Edition:
United Kingdom

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

2.74USD
5:42pm BST
Change (% chg)

$-0.08 (-2.84%)
Prev Close
$2.82
Open
$2.83
Day's High
$2.85
Day's Low
$2.72
Volume
51,071
Avg. Vol
251,213
52-wk High
$4.09
52-wk Low
$1.59

Chart for

About

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.... (more)
No analyst recommendations are available for .

Overall

Beta: 0.28
Market Cap(Mil.): €518.56
Shares Outstanding(Mil.): 156.41
Dividend: --
Yield (%): --

Financials

  ATRS.OQ Industry Sector
P/E (TTM): -- 32.19 32.74
EPS (TTM): -2.95 -- --
ROI: -- 13.89 14.38
ROE: -- 16.72 16.08

BRIEF-Antares Pharma Reports Q1 Loss Per Share Of $0.04

* ANTARES PHARMA REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

08 May 2018

BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA

* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION

05 Apr 2018

BRIEF-Antares Pharma Provides Xyosted™ Regulatory Update

* BELIEVES THAT IT DOES NOT NEED TO CONDUCT ANY NEW CLINICAL STUDIES TO SUPPORT RESUBMISSION

27 Mar 2018

BRIEF-Antares Pharma Q4 Loss Per Share $0.02

* ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

13 Mar 2018

BRIEF-Antares Pharma Provides Xyosted Regulatory Update

* ANTARES PHARMA INC - TYPE A MEETING HAS BEEN SCHEDULED WITH U.S. FOOD AND DRUG ADMINISTRATION ON FEBRUARY 21, 2018 FOR XYOSTED

16 Jan 2018

BRIEF-Antares Pharma Requests Type A Meeting With FDA Regarding Xyosted

* ANTARES PHARMA - WRITTEN REQUEST FOR A TYPE A MEETING HAS BEEN SUBMITTED TO FDA IN RESPONSE TO CRL RECEIVED REGARDING NDA FOR XYOSTED Source text for Eikon: Further company coverage:

21 Dec 2017

Earnings vs. Estimates

No consensus analysis data available.